Vendor Show
March 27, 2024 @ 7:30 am - 4:00 pm
The Delaware Valley Drug Metabolism: Vendor Show on Wednesday, March 27.
Non-presenting Vendors
- QPS LLC
- QRD Pharma
- BioRepository Resources
- LabLogic Systems, Inc
- Discovery Life Sciences / Gentest
- Eurofins Discovery Services
Schedule
Accurate mass spectrometry, particularly automated LC-MS/MS workflows using CID, has been crucial for investigating candidate modality metabolism in pharmaceutical drug development. Recent advancements, including improvements in duty cycle, enabled the integration of EAD into LC-MS/MS workflows, resulting in more confident characterizations of compounds of interest.
The study utilized the SCIEX OS software platform for data generation and analysis, employing the ZenoTOF 7600 system and Molecule Profiler software. Molecule Profiler allows the consolidation and ranking of structures based on EAD and CID data, making it a valuable tool for comparing MS/MS spectra and identifying unique fragments in a single results file.
In addition, I plan to speak briefly on two new transgenic strains recently developed. First, the Humanized minipig, which is used for therapeutic Ab studies. This model, if it cross-reacts, will be a better model than the NHP, as it does not produce ADAs to low and moderately immunogenic human antibodies. And finally, one of the biggest obstacles to using the minipig as a non-rodent specie is its size. I plan to briefly mention the newest transgenic strain, the micropig. This is genetically altered by introducing a mutation in the growth hormone receptor, resulting in a minipig that is less than half the size/weight of the standard minipig. The result will be a minipig that is anatomically and physiologically similar to humans, but the size of a beagle dog. This will revolutionize the industry. In fact, in Europe the default non-rodent specie is the minipig.
References:
1. Takakusa, H., et al. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs, Nucleic Acid Therapeutics, 2023; 33(3):83-94
2. Shadid, M., et al. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion, Expert Opinion on Drug Metabolism & Toxicology, 2021; 17(11):1281-1292
3. Kilanowska, A., et al. Studying in vitro metabolism of the first and second generation of antisense oligonucleotides with the use of ultra-high-performance liquid chromatograph coupled with quadrupole time-of-flight mass spectrometry, Analytical and Bioanalytical Chemistry, 2020; 412:7453-7467
4. Sips, L. et al. LC-MS quantification of oligonucleotides in biological matrices with SPE or hybridization extraction, Bioanalysis, 2019; 11(21):1941-1954
Coproporphyrin I and Coproporphyrin III are extracted from human plasma using a supported liquid extraction methodology. After recovering the analytes with ethyl acetate, the samples were evaporation and reconstitution with formic acid and EDTA solution. The resulting extracts were analyzed by LC-MS/MS detection. The analytes were separated from potential interferences using a reverse phase column and gradient conditions. A Sciex 6500+ mass spectrometer operating in positive electrospray mode was used to detect CP-I, CP-III, and the internal standards. Because CP-I and CP-III are endogenous compounds, calibrators and quality control samples were prepared in charcoal-stripped human plasma. The analytical range of the assay was 50.0 to 5000 pg/mL for both biomarkers.
Understanding the dose-dependent changes in these endogenous substrates of OATP1B1/1B3 makes it possible to identify investigation drugs with a potential DDI risk before conducting clinical DDI studies in patients. To aid in this decision-making process, a method of analysis for coproporphyrin I and coproporphyrin III in human plasma was developed and validated to support regulated clinical studies. This method was validated following the principles outlined in the FDA M10 bioanalytical method validation guidance and from the AAPS “Biomarker Assay Validation by Mass Spectrometry” white paper. Included in the validation were experiments to measure accuracy and precision in an authentic and surrogate matrix, parallelism, and stability experiments.
InSilicoTrials Technologies has developed a cloud-based bio-simulation platform aimed at democratizing the use of modeling and simulation. This platform supports the creation of dashboard applications for decision-makers, streamlining the transition from traditional methods to advanced in silico trials. The platform hosts healthcare simulation tools – coming from our network of 70+ (and growing!) world-renowned scientific partners – for different bench, preclinical and clinical evaluations, and for diverse disease areas.
This presentation will also discuss two use cases of in silico trials conducted on the InSilicoTrials.com platform. The first illustrates the potential of bio simulation to improve the early preclinical assessment of drug-induced cardiotoxicity risks. The second use case demonstrates the application of virtual patient generation to evaluate treatment effects in multiple sclerosis, showcasing the platform’s capability to enhance and expedite clinical decision-making.
Bioanalytical assay creation involves a sensitive LC-MS/MS method to detect low levels of toxic payload in plasma. This method typically needs to be adapted for analysis of the payload in the targeted tumor tissue as well, and that analysis is complicated by the need to collect a small (1-5 mg) tumor biopsy. Additionally, ligand binding assays for the intact ADC need to be developed, and these assays are impacted by the heterogenous distribution of different numbers of payload molecules attached to the targeting protein. Finally, the stimulation of the immune system by these molecules needs to be assessed, with general anti-drug antibodies being differentiated from neutralizing antibodies.
This presentation will describe development of each of the bioanalytical assays needed to support the advancement of ADCs from the candidate selection phase through the regulatory submission process.
In the current presentation, besides a short introduction to the emerging molecule groups the most frequently raised questions and possible answers will be presented based on the regulatory guidance documents and on in-house experience. Through case studies, we demonstrate different approaches tailored based on the chemical structure and physical-chemical properties of the various molecule groups for in vitro ADME studies.
Regulatory agencies mandate pre clinical tissue distribution studies before permitting the study of radiolabeled drug candidates in human subjects. QWBA tissue concentration data supports radiation dosimetry required by regulatory agencies. Radiation absorbed doses (RADhuman) for a single administration of a carbon 14 drug candidate to human subjects must not exceed 3000 mrem for active blood forming organs, gonads, eye lens, and whole body. RADhuman for all other tissues must not exceed 5000 mrem after a single dose of radioactivity. The ICRP established a 1 mSv limit for human whole-body exposure. Conducting a QWBA study is essential to ensure the safety of human subjects administered a dose of carbon 14 radioactivity. Radiation dosimetry is typically based on a 100 µCi single dose of radioactivity administered to human adult subjects.
In summary, quantifying the distribution of radiolabeled drug candidates in tissues, determining elimination rates, and calculating radiation dosimetry prior to conducting human radiolabeled clinical trials are important for drug development.